PHIO Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Phio Pharmaceuticals Corp | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerPHIO

Market Cap13.1M

Cash RunwayRunway > 12 months

Next Catalystn/a

Public Research Snapshot

Phio Pharmaceuticals Corp is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Discovery (Preclinical) using Sirna.

Pipeline

Asset	Indication	Modality	Stage	Public Note
Who we are	n/a	Sirna	n/a	Public pipeline row
Discovery	n/a	n/a	Preclinical	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

literature_publication | A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
literature_publication | Patients' selection and trial matching in early-phase oncology clinical trials.
literature_publication | Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.
literature_publication | Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial.
asset_name | Discovery

Want the full PHIO research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.